The past few years have witnessed huge changes in the approach to creating new
anticancer agents, in part due to sophisticated new technologies and computer tools, and in …

The rise of targeted therapy for solid tumours over the past decade has yielded a cornucopia
of novel agents across an array of cancers. Amidst multiple acclaimed successes, targeted …

In the evolving landscape of precision oncology, genomic characterization of tumor has
become crucial in order to move toward a molecular-based therapy for the vast majority of …

Most of the significant recent advances in cancer treatment have been based on the great
strides that have been made in our understanding of the underlying biology of the disease …

Early‐phase clinical development in oncology has evolved dramatically with the deciphering
of the human genome in 2004. Genomic analysis and the tools identifying genetically …

The treatment of patients with advanced malignancies has undergone remarkable change in
the last few years. While in the past decisions about systemic therapy were largely based on …

Simple Summary The primary goal of any intervention in oncology is to improve overall
survival and/or quality of life. The gold-standard approach to demonstrate that this goal has …

Cancer is a spectrum of genetic diseases resulting from various mutations in specific genes.
These mutations, which may either abrogate gene function or increase gene function (by …

Over the past decade, molecular-targeted therapies have been added to cytotoxic and anti-
endocrine drugs in the treatment of cancer, with the aim to target the molecular pathways …

Small-molecule drugs have enabled the practice of precision oncology for genetically
defined patient populations since the first approval of imatinib in 2001. Scientific and …